Archrock Inc
Change company Symbol lookup
Select an option...
AROC Archrock Inc
PACK Ranpak Holdings Corp
NVEE NV5 Global Inc
YARIY Yara International ASA
HYB New America High Income Fund
ACV Virtus Diversified Income & Convertible Fund
XLO Xilio Therapeutics Inc
ORN Orion Group Holdings Inc
SMHI SEACOR Marine Holdings Inc
ASC Ardmore Shipping Corp
Go

Energy : Energy Equipment & Services | Small Cap Value
Company profile

Archrock, Inc. is an energy infrastructure company with a pure-play focus on midstream natural gas compression. The Company is a provider of natural gas compression services to customers in the oil and natural gas industry throughout the United States, in terms of total compression fleet horsepower and a supplier of aftermarket services to customers that own compression equipment in the United States. The natural gas that it helps transport satisfies demand from electricity generation, heating and cooking and the industrial and manufacturing sectors. It has two segments. Its Contract Operations segment is comprised of its owned fleet of natural gas compression equipment that it uses to provide operations services to its customers. Its Aftermarket Services segment provides a full range of services to support the compression needs of its customers, which owns compression equipment, including operations, maintenance, overhaul and reconfiguration services and sales of parts and components.

Closing Price
$8.00
Day's Change
0.07 (0.88%)
Bid
--
Ask
--
B/A Size
--
Day's High
8.13
Day's Low
7.90
Volume
(Heavy Day)
Volume:
1,308,672

10-day average volume:
1,011,290
1,308,672

Lifshitz Law PLLC Announces Investigations of First Solar, Inc. (NASDAQ: FSLR), Oak Street Health, Inc. (NYSE: OSH), Talis Biomedical (NASDAQ: TLIS), and Talkspace Inc. (NASDAQ: TALK)

4:01 pm ET March 29, 2022 (Globe Newswire) Print

EQNX::TICKER_START (NASDAQ:FSLR),(NYSE:OSH),(NasdaqGM:TLIS),(NASDAQ:TALK), EQNX::TICKER_END

First Solar, Inc. (NASDAQ: FSLR)

Lifshitz Law PLLC announces that a class action complaint was filed on behalf of shareholders of First Solar alleging that Defendants made repeated misrepresentations to investors regarding the development of its newest "Series 6" solar module, the cost per unit it could achieve with that module, and the impact the changeover to this new product would have on the viability of its other business segments. As a result of Defendants' alleged misrepresentations, First Solar common stock traded at artificially inflated prices during the Class Period.

If you are a First Solar investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Oak Street Health, Inc. (NYSE: OSH)

Lifshitz Law PLLC announces that a class action complaint was filed against Oak Street Health alleging Defendants failed to disclose to investors: (i) that Oak Street maintained relationships with third-party marketing agents likely to provoke law enforcement scrutiny; (ii) that Oak Street was providing free transportation to federal health care beneficiaries in a manner that would provoke law enforcement scrutiny; (iii) that these activities may be violations of the False Claims Act; (iv) that, as such, Oak Street was at heightened risk of investigation by the DOJ and/or other federal law enforcement agencies; (v) that, as a result, Oak Street was subject to adverse impacts related to defense and settlement costs and diversion of management resources; and (vi) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you are an Oak Street Health investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Talis Biomedical (NASDAQ: TLIS)

Lifshitz Law PLLC announces that a class action complaint was filed against Talis Biomedical alleging that Defendants failed to disclose to investors: (i) that the comparator assay in the primary study lacked sufficient sensitivity to support Talis's EUA application for Talis One COVID-19 test; (ii) that, as a result, Talis was reasonably likely to experience delays in obtaining regulatory approval for the Talis One COVID-19 test; (iii) that, as a result, the Company's commercialization timeline would be significantly delayed; and (iv) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

If you are a Talis Biomedical investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Talkspace Inc. (NASDAQ: TALK)

Lifshitz Law PLLC announces that a class action complaint has been filed against Talkspace alleging that, in an attempt to secure shareholder support for the Merger, on May 28, 2021, Defendants issued a materially false and misleading Preliminary Proxy on Schedule 14A. The Proxy, which recommended that HEIC shareholders vote in favor of the Merger, allegedly misrepresented Talkspace's business, financials, and prospects, by omitting, among other things, that: (i) Talkspace was experiencing significantly increased online advertising costs in its business-to-consumer ("B2C") channel since the start of 2021; (ii) Talkspace was experiencing lower conversion rates in its online advertising in its B2C business; (iii) Talkspace was experiencing increased customer acquisition costs and more tepid B2C demand than represented to investors; (iv) Talkspace was suffering from ballooning customer acquisition costs and worsening growth and gross margin trends; (v) Talkspace had overvalued its accounts receivables from certain of its health plan clients in its business-to-business channel, which amounts required adjustment downward; and (vi) as a result of the foregoing, Talkspace's 2021 financial guidance was not achievable and lacked any reasonable basis in fact. The Complaint further alleges that after the Merger closed the Proxy was revealed to be materially false and misleading, causing the price of Talkspace common stock to substantially decline and Talkspace investors to suffer damages under the Exchange Act.

If you are a Talkspace investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

ATTORNEY ADVERTISING.(C) 2022 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:

Joshua M. Lifshitz, Esq.

Lifshitz Law PLCC

Phone: 516-493-9780

Facsimile: 516-280-7376

Email: jml@jlclasslaw.com

https://ml.globenewswire.com/media/Mzk2NGE0NjItNWJlMy00MjdjLWI5NGYtZmRjZDcwNGZkZTA0LTEyMTY1ODk=/tiny/Lifshitz-Law-Firm-P-C-.png

https://ml.globenewswire.com/media/Mzk2NGE0NjItNWJlMy00MjdjLWI5NGYtZmRjZDcwNGZkZTA0LTEyMTY1ODk=/tiny/Lifshitz-Law-Firm-P-C-.png

comtex tracking

COMTEX_404953703/2010/2022-03-29T16:01:20

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.